What You Should Know:
- Debiopharm, a leading independent biopharmaceutical company, and ThinkingNodeLife.ai (TNL), a pioneer in AI-powered drug discovery, today announced a groundbreaking partnership to propel the development of a cutting-edge cancer drug.
- This strategic partnership combines Debiopharm's deep pharmaceutical expertise with TNL's revolutionary AI Digital Cells Lab platform, unlocking new frontiers in cancer treatment innovation.
Unlocking the Hidden Potential of a
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Deepcell & NVIDIA Partner to Develop Generative AI Models for Single Cell Morphology
What You Should Know:
Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced a research collaboration with NVIDIA to accelerate the development and adoption of advanced computer vision solutions in life sciences.Deepcell will incorporate NVIDIA AI into its single cell analysis technology, working collaboratively with NVIDIA to codevelop new uses for generative AI and multimodal applications in cell biology. The
Read More
Clinical Trial Payments: Optimizing the Path Forward for Site Payments
Escalating competition for clinical trial sites, in tandem with other industry-wide challenges such as changing regulations; a lack of bandwidth and resources; identifying ideal sites and recruiting and retaining patients, are posing significant obstacles for sponsors and site teams within a global study portfolio, particularly in relation to clinical trial payments. Factors such as decentralized clinical trials, inflation and site attrition contribute to inconsistencies and financial confusion,
Read More
Lessons Learned from the AIDS Crisis to Combat Congenital Syphilis
Public health learnings and data gathered over the 40 years of the AIDS crisis can help officials tackle the rise of congenital syphilis, which increased 755% from 2012 to 2021 and another 30% in 2022. The Centers for Disease Control and Prevention (CDC) recently noted “missed opportunities for prevention, primarily timely testing and appropriate treatment of syphilis during pregnancy” as contributing factors to its meteoric rise.
Read More
Veracyte Acquires C2i Genomics for $70M, Expanding into Minimal Residual Disease Detection
What You Should Know:
- Veracyte, Inc. (Nasdaq: VCYT), a cancer diagnostics company acquires C2i Genomics, Inc., a pioneer in minimal residual disease (MRD) detection.
- Under the terms of the agreement, Veracyte will pay $70 million in Veracyte shares at closing, and up to an additional $25 million based on the achievement of future performance milestones over the next two years, payable in Veracyte shares or cash at Veracyte’s election.
- This strategic move positions Veracyte to
Read More
Caris & Flatiron Team Up: Next-Level RWD Supercharges Cancer Drug Discovery
What You Should Know:
Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionise healthcare and improve the human condition using molecular science and AI, and Flatiron Health, a leading health-tech company transforming evidence generation through an engaged care network, oncology-specific expertise, and fit-for-purpose scientific methods and tools, today
Read More
Atropos Health Partners With Every Cure: A New Lifeline For Underserved Populations Via Streamlined Drug Repurposing
What You Should Know:
Atropos Health, the pioneer in translating real-world clinical data into personalized real-world evidence and insights, today announced a partnership with Every Cure, a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can so that patients don’t suffer while cures hide on the pharmacy shelf.The collaboration allows Every Cure to leverage GENEVA OS™ and data from the
Read More
Amgen Builds Generative AI Models for Human Data Analysis and Drug Discovery
What You Should Know:
- Amgen, a global leader in biotechnology, is embarking on a groundbreaking venture: Project Freyja.
- The new initiative will harness the power of an NVIDIA DGX SuperPOD, christened after the Norse goddess of prediction, to accelerate drug discovery and development through AI-powered insights from one of the world's largest human datasets.
Advance Drug Discovery Using NVIDIA DGX SuperPOD-Powered Insight
Human Diversity Atlas: Freyja will map the landscape
Read More
QuantHealth Scores $17M to Supercharge AI-Driven Clinical Trials
What You Should Know:
- In a decisive move towards faster and more efficient drug development, QuantHealth, a leading AI-powered clinical trial design company, has secured a strategic investment of $17M.
- The new capital, fueled by Accenture Ventures alongside a prominent CRO and additional investors, bolsters QuantHealth's total Series A funding and propels its mission to revolutionize clinical trials through AI simulations.
Saving Millions with 86% Predictive
Read More
Deloitte Unveils Atlas AI: Accelerating Drug Discovery with Generative AI and NVIDIA Power
What You Should Know:
- Deloitte, a global leader in professional services, has unveiled Atlas AI, a groundbreaking addition to its Quartz AI™ suite, marking a significant leap forward in life sciences and healthcare (LSHC).
- Built on the NVIDIA AI and NVIDIA Omniverse™ platforms, Atlas AI empowers scientists with novel tools to expedite drug discovery and bring life-saving treatments to market faster.
Harnessing the Power of Generative AI
Atlas AI boasts a unique arsenal of AI
Read More
